Stephen Willey
Stock Analyst at Stifel
(3.39)
# 976
Out of 4,911 analysts
132
Total ratings
43.62%
Success rate
5.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Reinstates: Buy | $30 | $13.77 | +117.86% | 1 | Jul 1, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $28 | $13.29 | +110.68% | 1 | Jun 25, 2025 | |
| INCY Incyte | Upgrades: Buy | $75 → $107 | $70.20 | +52.42% | 6 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Hold | $6 → $5 | $1.71 | +192.40% | 3 | May 14, 2025 | |
| EXEL Exelixis | Maintains: Hold | $36 → $38 | $45.60 | -16.67% | 18 | May 14, 2025 | |
| BOLT Bolt Biotherapeutics | Maintains: Hold | $25 → $20 | $6.43 | +211.04% | 4 | May 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $36 → $35 | $11.52 | +203.82% | 5 | Apr 9, 2025 | |
| NKTX Nkarta | Maintains: Buy | $15 → $14 | $2.16 | +548.15% | 3 | Mar 27, 2025 | |
| VOR Vor Biopharma | Maintains: Buy | $12 → $5 | $2.20 | +127.27% | 5 | Mar 21, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $12 → $10 | $5.11 | +95.69% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.26 | +217.46% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $97 → $96 | $103.95 | -7.65% | 6 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $27 → $2.5 | $1.27 | +96.85% | 7 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $120 | $1.82 | +6,493.41% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $28 | $13.34 | +109.97% | 6 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $11.77 | +299.32% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $0.88 | +353.05% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $34 → $3 | $2.15 | +39.53% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $7 | $6.74 | +3.86% | 10 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $1.53 | +161.44% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $30.30 | +104.65% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $3.18 | +183.02% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.10 | +471.43% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.47 | +19,491.84% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $2.33 | +801.29% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $1.10 | +263.64% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $328.81 | -62.59% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $42.25 | +11.26% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $59.01 | +84.71% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $18.71 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $6.91 | +232.85% | 5 | Feb 7, 2018 |
Celcuity
Jul 1, 2025
Reinstates: Buy
Price Target: $30
Current: $13.77
Upside: +117.86%
Crescent Biopharma
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $13.29
Upside: +110.68%
Incyte
Jun 16, 2025
Upgrades: Buy
Price Target: $75 → $107
Current: $70.20
Upside: +52.42%
MacroGenics
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $1.71
Upside: +192.40%
Exelixis
May 14, 2025
Maintains: Hold
Price Target: $36 → $38
Current: $45.60
Upside: -16.67%
Bolt Biotherapeutics
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $6.43
Upside: +211.04%
Nurix Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $36 → $35
Current: $11.52
Upside: +203.82%
Nkarta
Mar 27, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $2.16
Upside: +548.15%
Vor Biopharma
Mar 21, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $2.20
Upside: +127.27%
AbCellera Biologics
Feb 28, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $5.11
Upside: +95.69%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.26
Upside: +217.46%
Feb 21, 2025
Maintains: Buy
Price Target: $97 → $96
Current: $103.95
Upside: -7.65%
Jan 10, 2025
Downgrades: Hold
Price Target: $27 → $2.5
Current: $1.27
Upside: +96.85%
Nov 14, 2024
Maintains: Buy
Price Target: $150 → $120
Current: $1.82
Upside: +6,493.41%
Oct 28, 2024
Maintains: Buy
Price Target: $21 → $28
Current: $13.34
Upside: +109.97%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $11.77
Upside: +299.32%
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $0.88
Upside: +353.05%
Jul 9, 2024
Downgrades: Hold
Price Target: $34 → $3
Current: $2.15
Upside: +39.53%
Apr 12, 2024
Maintains: Hold
Price Target: $7
Current: $6.74
Upside: +3.86%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $1.53
Upside: +161.44%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $30.30
Upside: +104.65%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $3.18
Upside: +183.02%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $2.10
Upside: +471.43%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.47
Upside: +19,491.84%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $2.33
Upside: +801.29%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $1.10
Upside: +263.64%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $328.81
Upside: -62.59%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $42.25
Upside: +11.26%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $59.01
Upside: +84.71%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $18.71
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $6.91
Upside: +232.85%